PUBLISHER: Grand View Research | PRODUCT CODE: 2089801
PUBLISHER: Grand View Research | PRODUCT CODE: 2089801
The global insulin pump market size was valued at USD 7.2 billion in 2025 and is projected to grow from USD 7.8 billion in 2026 to USD 13.1 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. North America insulin pump market held the largest share of 45.4% of the global market in 2025. The market expansion is primarily driven by the growing elderly population, rising diabetes incidence, and increasing obesity prevalence.
Companies are developing next-generation insulin pumps with advanced technology to enhance compliance and integration with IT devices, further driving market growth. Innovations such as home infusion therapy and artificial pancreas technology are expected to create significant growth opportunities in the near future. Additionally, as insulin pumps gain popularity, markets in both developed and developing countries are expanding. An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market. Obesity is a major factor causing diabetes, leading to increased incidences of diabetes-associated ophthalmic disorders. Risk factors, such as obesity, smoking, and high cholesterol, are expected to boost the prevalence of type II diabetes. According to the World Health Organization (WHO), recent global projections indicate that more than half of the world's adult population (approximately 3.8 billion people) could be living with overweight or obesity by 2050 if current trends continue.
Furthermore, there is a notable increase in the number of elderly individuals prone to developing diabetic neuropathy. The geriatric demographic is particularly vulnerable due to factors such as longer diabetes duration, decreased nerve regeneration capacity, and comorbidities that can exacerbate neuropathic symptoms. As the global population ages, the World Health Organization (WHO) predicts that the number of people aged 60 years and older will increase to 1 in 6 by 2030, rising from 1 billion in 2020 to 1.4 billion recently. The global population of people aged 60 years and older is expected to double to 2.1 billion by 2050, with individuals aged 80 years or older set to triple to 426 million. This demographic shift will lead to a higher likelihood of chronic conditions like diabetes and peripheral neuropathy, increasing the risk of diabetic neuropathy among seniors.
The insulin pump industry growth is anticipated to be driven by the technological advancements and manufacturers competing for product approval in key application area drives the market forwards. As more companies receive FDA approval, their adoption has notably increased. For instance, in April 2023, the FDA approved the Medtronic MiniMed 780G System, an advanced automated insulin delivery system for individuals aged 7 and older with type 1 diabetes. It is the world's first insulin pump with 'Meal Detection Technology'. This system uses continuous glucose monitoring (CGM) to track glucose levels and automatically adjusts insulin delivery. It includes a glucose sensor, wireless data transmission, and a smart insulin pump. Clinical trials and real-world evidence confirm its safety and effectiveness in managing diabetes, enhancing users' glucose control and quality of life. With the anticipated expansion of the insulin pump market and supported benefits such as better blood sugar control and improved quality of life, insulin pumps are poised to significantly empower individuals with diabetes, leading to healthier and more satisfying lifestyles.
"Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes and now for the first time, the MiniMed 780G system addresses this unmet need with automatic, real-time insulin corrections"
Key Professional at Medtronic plc
Increasing government initiatives for global awareness about medicare policies and the management of diabetes are also fueling market growth. Furthermore, there has been a rise in healthcare spending and an increase in the demand for improved tubeless insulin pumps that are both discreet and user-friendly. This is expected to drive market growth during the forecast period.
"We launched this unique contest in the community to better understand how patients describe diabetic nerve pain of their feet in their own terms.
By redefining the symptoms using their own words, our goal is to help diabetic peripheral neuropathy patients and their health care providers start using common language to talk about their symptoms, fostering more productive conversations around diagnosis, disease management and potential solutions."
Dr. Lizandra Marcondes, Head Medical Affairs Averitas Pharma
Innovations in integrating advanced technology and improving patient outcomes is driving market growth. The latest developments include the creation of closed-loop systems, also known as artificial pancreas systems, which automate insulin delivery based on real-time glucose monitoring. With their seamless integration with continuous glucose monitoring (CGM) technology and demonstrated effectiveness in blood sugar management, insulin pumps are becoming essential tools in the fight against diabetes. Systems such as a pump connected to an automated insulin delivery (AID) system, paired with a connected insulin pen or smart pen cap, enhance diabetes management. When combined with a powerful continuous glucose monitor (CGM) sensor, this technology offers precise and efficient blood glucose control. Further, the incorporation of wireless connectivity and mobile app integration allows for seamless data tracking and remote monitoring, providing healthcare providers with valuable insights into patient management. Moreover, advancements in pump design, such as smaller, more discreet devices and pain-free insertion techniques, are increasing patient comfort and adherence.
Global Insulin Pump Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global insulin pump market report on the basis of product, system architecture, end use and region: